NEW
YORK, July 4, 2024 /PRNewswire/ -- The
global gastroesophageal reflux disease (GERD) market
size is estimated to grow by USD 879.8
million from 2024-2028, according to Technavio. The market
is estimated to grow at a CAGR of 3.2% during the
forecast period. Rising geriatric population is
driving market growth, with a trend towards rising
prevalence of obesity. However, increased preference for
complementary and alternative medicine cam poses a challenge.
Key market players include Abbott Laboratories, Alkem Laboratories
Ltd., Apotex Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Bayer
AG, Cipla Inc., Dr Reddys Laboratories Ltd., Eisai Co. Ltd.,
Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, inovapharma.com,
Johnson and Johnson Services Inc., Lupin Ltd., Perrigo Co. Plc,
Pfizer Inc., SRS Life Sciences Pte. Ltd., Sun Pharmaceutical
Industries Ltd., Takeda Pharmaceutical Co. Ltd., and The Procter
and Gamble Co..
Get a detailed analysis on regions, market
segments, customer landscape, and companies - Click for the
snapshot of this report
Forecast
period
|
2024-2028
|
Base Year
|
2023
|
Historic
Data
|
2018 - 2022
|
Segment
Covered
|
Route Of Administration
(Oral and Parenteral), Type (Antacid, PPI, H2 receptor antagonist
drugs, and Pro-Kinetic drugs), and Geography (North America,
Europe, Asia, and Rest of World (ROW))
|
Region
Covered
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Key companies
profiled
|
Abbott Laboratories,
Alkem Laboratories Ltd., Apotex Inc., AstraZeneca Plc, Aurobindo
Pharma Ltd., Bayer AG, Cipla Inc., Dr Reddys Laboratories Ltd.,
Eisai Co. Ltd., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc,
inovapharma.com, Johnson and Johnson Services Inc., Lupin Ltd.,
Perrigo Co. Plc, Pfizer Inc., SRS Life Sciences Pte. Ltd., Sun
Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., and
The Procter and Gamble Co.
|
Key Market Trends Fueling Growth
The obesity epidemic has fueled growing interest in the
relationship between obesity and gastroesophageal reflux disease
(GERD), including esophageal erosions, Barrett's esophagus, and
esophageal adenocarcinoma. Obesity's association with GERD is
supported by numerous studies, revealing increased symptoms in
overweight individuals with normal BMIs. The escalating obesity
rates lead to higher healthcare costs due to associated chronic
diseases like cardiovascular diseases, type 2 diabetes, and certain
cancers. The prevalence of obesity among US children and
adolescents, currently at 19.3%, increases the risk of GERD and
related disorders. This trend is expected to boost the demand for
GERD drugs, contributing to the market's growth during the forecast
period.
The Gastroesophageal Reflux Disease (GERD) market is
experiencing significant growth due to increasing prevalence and
awareness of the condition. According to recent studies, the global
market for GERD treatments is projected to expand at a steady pace.
Key drivers include an aging population, rising obesity rates, and
increasing consumption of processed foods. Common symptoms of GERD,
such as heartburn and acid regurgitation, are leading to increased
demand for medications and surgical interventions. Additionally,
advancements in technology and research are leading to the
development of new and effective treatments. Overall, the GERD
market is expected to continue its upward trend in the coming
years.
Research report provides comprehensive data on
impact of trend. For more details- Download a Sample
Report
Market Challenges
• The use of
complementary and alternative medicines (CAM) for gastroesophageal
reflux disease (GERD) poses a significant challenge to the global
GERD market growth. Over 70% of Americans have tried these
treatments, and their popularity is increasing due to growing
awareness. Commonly used CAMs include acupuncture, massage, herbs
like chamomile, and vitamins A, C, and E. These therapies aim to
ease symptoms and involve physical exercises, dietary changes, and
mind-body therapies. The increasing adoption of CAMs restricts the
market's growth during the forecast period.
• The
Gastroesophageal Reflux Disease (GERD) market faces several
challenges. Digestive and esophageal issues, such as acid reflux
and heartburn, are common health concerns. Drugs like Proton Pump
Inhibitors (PPIs) and H2 blockers are used to treat GERD symptoms.
However, long-term use of these drugs can lead to side effects and
resistance. Additionally, the rising prevalence of obesity and
unhealthy diets contributes to the increasing incidence of GERD.
Furthermore, the high cost of treatment and lack of awareness in
some regions pose significant challenges to market growth. The
market requires innovative solutions, such as natural remedies and
preventive measures, to address these challenges and improve
patient outcomes.
For more insights on driver and
challenges - Download a Sample Report
Segment Overview
This gastroesophageal reflux disease (gerd) market report
extensively covers market segmentation by
- Route Of Administration
- Type
- 2.1 Antacid
- 2.2 PPI
- 2.3 H2 receptor antagonist drugs
- 2.4 Pro-Kinetic drugs
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 Oral-
For more information on market segmentation with
geographical analysis including forecast (2024-2028) and historic
data (2018 - 2022) - Download a Sample Report
Research Analysis
The GERD market encompasses a range of interventions for the
diagnosis, symptom management, and disease management of
Gastroesophageal Reflux Disease (GERD). This includes diagnostic
tests such as esophageal pH monitoring and endoscopic procedures
like esophagogastroduodenoscopy (EGD). Proton pump inhibitors
(PPIs) and antacids serve as prescription medications for acid
reflux symptom relief. Lifestyle changes, such as diet
modifications and weight loss, are also integral components of GERD
treatment. Patients may also benefit from clinical trials exploring
new therapeutic approaches and patient education resources to
enhance their understanding of the condition. Symptoms like
heartburn and regurgitation are common indicators of GERD, while
gastric acid plays a crucial role in the disease pathophysiology.
Overall, the GERD market aims to provide effective solutions for
symptom management and disease control.
Market Research Overview
Gastroesophageal Reflux Disease (GERD) is a digestive disorder
characterized by the chronic reversal of stomach contents into the
esophagus. This condition can cause various symptoms such as
heartburn, regurgitation, and chest pain. The global market for
GERD treatments is significant, driven by increasing prevalence,
growing awareness, and advancements in technology. The market
comprises various segments, including pharmaceuticals, diagnostics,
and surgical interventions. The pharmaceutical segment dominates
due to the availability of numerous drugs for symptomatic relief.
Diagnostics play a crucial role in accurate diagnosis, while
surgical interventions offer long-term solutions for severe cases.
The market is expected to grow due to rising healthcare
expenditures, an aging population, and increasing obesity rates.
Additionally, the market is witnessing the entry of new players and
technological advancements, leading to increased competition and
innovation.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Route Of Administration
-
- Type
-
- Antacid
- PPI
- H2 Receptor Antagonist Drugs
- Pro-Kinetic Drugs
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/gastroesophageal-reflux-disease-gerd-market-size-is-set-to-grow-by-usd-879-8-million-from-2024-2028--rising-geriatric-population-to-boost-the-market-growth-technavio-302188831.html
SOURCE Technavio